(2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg) + Placebo for depressive disorder, treatment-resistant

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 22 Jul 2024: Trial registered, NCT06511908
  2. 6 Nov 2024: Trial started, NCT06511908

The trials

NCT06511908: Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

State
Under way
Phase
Phase 2
People
50 planned
Started
6 Nov 2024
Primary completion
1 Jul 2027
Arms
1, 2
Results
None posted
  1. 22 Jul 2024: Trial registered
  2. 6 Nov 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.